Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.
Literal federal measure citations: H.R. 1
Source-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 21, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- THE NICKLES GROUP, LLC
- Client
- AMGEN
- Filing UUID
- 5f89be49-a6de-4fd1-964d-7d6f8c298b33
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to tariffs. Issues related to drug pricing.
Monitored implementation of P.L. 117-169, the Inflation Reduction Act as it relates to drug pricing. Issues related to biosimilars. Monitored issues related to cardiovascular health. Issues related to pharmacy benefit management reforms. Monitored issues related to dialysis services. Issues related to the Most Favored Nation drug pricing.
Issues related to pharmacy benefit management reforms. Issues related to cardiovascular care. Issues related to drug pricing. Issues related to the drug supply chain. S. 3788, Clear Labels Act. S. 3014, Ensuring Timely Access to Generics Act of 2025; S. 1954, Biosimilar Red Tape Elimination Act; S. 2658, Medication Affordability and Patent Integrity Act.
Literal federal measure citations: S. 3788, S. 3014, S. 1954, S. 2658
Monitored issues related to intellectual property.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.